InNexus Biotechnology Inc. To Host A Webcast Teleconference Detailing Recent News on Royalty Pharma Agreement & Preliminary Results of DXL625 Animal Study

BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--Feb 8, 2008 - InNexus Biotechnology Inc. (OTCBB: IXSBF)(TSX VENTURE: IXS), (http://www.ixsbio.com) Chairman and CEO, Jeff Morhet will host a webcast teleconference on Monday, February 11, 2008 at 11:00 AM ET to discuss recent announcement with Royalty Pharma and preliminary results of an in vivo animal study exhibiting DXL625 (CD20)'s efficacy in reducing the growth rate of lymphoma cancer tumors.

Teleconference Details

InNexus will host an informative teleconference on Monday, February 11, 2008 at 11:00 AM ET to discuss its recently announced agreement with Royalty Pharma. Jeff Morhet, Chairman and CEO of InNexus, along with Wade Brooksby, Chief Financial Officer, will also discuss company focus and operations including the pre-clinical program of its lead product, DXL625 (CD20).

Participants can listen to the teleconference by logging onto: http://www.vcall.com/IC/CEPage.asp?ID=125980 or dialing 866-585-6398. International callers can dial in using 416-849-9626. A playback of the teleconference will be available using the replay number 866-245-6755 and international callers can call using 416-915-1035 pass code 995867. The playback will be available for seven days after the live teleconference.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development facilities provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.

Contact

InNexus Biotechnology Inc.
Jeff Morhet, Chairman & Chief Executive Officer
Wade Brooksby, Chief Financial Officer
480-862-7500
or
The Investor Relations Group
Christine Berni, 212-825-3210
cberni@investorrelationsgroup.com
or
Media
Janet Vasquez or Michaela Heller, 212-825-3210
jvasquez@investorrelationsgroup.com

Posted: February 2008

View comments

Hide
(web4)